Thomas J Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7657471/publications.pdf

Version: 2024-02-01

39 papers 4,573 citations

279701 23 h-index 315616 38 g-index

40 all docs

40 docs citations

40 times ranked

5854 citing authors

#	Article	IF	CITATIONS
1	Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration. PLoS Medicine, 2008, 5, e45.	3.9	1,935
2	Effects of Diet and Sodium Intake on Blood Pressure: Subgroup Analysis of the DASH-Sodium Trial. Annals of Internal Medicine, 2001, 135, 1019.	2.0	475
3	Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998-2005. Archives of Internal Medicine, 2007, 167, 1752.	4.3	376
4	Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. JAMA Internal Medicine, 2014, 174, 1930.	2.6	246
5	Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016. JAMA Internal Medicine, 2018, 178, 1451.	2.6	219
6	Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. JAMA Internal Medicine, 2017, 177, 274.	2.6	163
7	Suicidal Behavior and Depression in Smoking Cessation Treatments. PLoS ONE, 2011, 6, e27016.	1.1	128
8	Effect of Dietary Patterns on Ambulatory Blood Pressure. Hypertension, 1999, 34, 472-477.	1.3	124
9	Reported Adverse Drug Events in Infants and Children Under 2 Years of Age. Pediatrics, 2002, 110, e53-e53.	1.0	111
10	Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products. Archives of Internal Medicine, 2004, 164, 1192.	4.3	97
11	Prescription Drugs Associated with Reports of Violence Towards Others. PLoS ONE, 2010, 5, e15337.	1.1	75
12	Dabigatran, bleeding, and the regulators. BMJ, The, 2014, 349, g4517-g4517.	3.0	70
13	The Fate of FDA Postapproval Studies. New England Journal of Medicine, 2017, 377, 1114-1117.	13.9	64
14	Reported medication errors associated with methotrexate. American Journal of Health-System Pharmacy, 2004, 61, 1380-1384.	0.5	55
15	The FDA and New Safety Warnings. Archives of Internal Medicine, 2012, 172, 78.	4.3	43
16	Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open, 2020, 10, e039978.	0.8	42
17	Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015–2017: a cross-sectional study. BMJ Open, 2020, 10, e038863.	0.8	38
18	Electronic Health Data for Postmarket Surveillance: A Vision Not Realized. Drug Safety, 2015, 38, 601-610.	1.4	36

#	Article	IF	Citations
19	Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiology and Drug Safety, 2016, 25, 713-718.	0.9	33
20	Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline. Annals of Pharmacotherapy, 2010, 44, 1389-1394.	0.9	29
21	Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 2021, 97, e1266-e1275.	1.5	29
22	Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis and Hemostasis, 2012, 38, 905-907.	1.5	28
23	Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products. JAMA Internal Medicine, 2021, 181, 52.	2.6	25
24	latrogenic Effects of COX-2 Inhibitors in the US Population. Drug Safety, 2009, 32, 335-343.	1.4	24
25	Risk of psychiatric side effects with varenicline. BMJ: British Medical Journal, 2009, 339, b4964-b4964.	2.4	23
26	Assessment of Patterns of Potentially Unsafe Use of Zolpidem. JAMA Internal Medicine, 2018, 178, 1275.	2.6	18
27	Globalization of clinical trials: Variation in estimated regional costs of pivotal trials, 2015–2016. Clinical Trials, 2019, 16, 329-333.	0.7	12
28	Estimated costs of pivotal trials for U.S. Food and Drug Administration–approved cancer drugs, 2015–2017. Clinical Trials, 2020, 17, 119-125.	0.7	12
29	US Food and Drug Administration Safety Advisories and Reporting to theÂAdverse Event Reporting System (FAERS). Pharmaceutical Medicine, 2020, 34, 135-140.	1.0	9
30	Safety and effectiveness of <scp>NMDA</scp> receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy, 2022, 42, 567-579.	1.2	8
31	The Harms of Antipsychotic Drugs: Evidence from Key Studies. Drug Safety, 2017, 40, 3-14.	1.4	7
32	Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional study. BMJ Open, 2021, 11, e048528.	0.8	5
33	Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. JAMA Oncology, 2021, 7, 1720-1721.	3.4	4
34	Antidepressants increase, rather than decrease, risk of suicidal behaviours in younger patients. BMJ, The, 2014, 349, g5626-g5626.	3.0	2
35	Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018. Annals of Internal Medicine, 2020, 173, 956-963.	2.0	2
36	Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin. Psychiatric Services, 2021, 72, 77-80.	1.1	2

THOMAS J MOORE

#	Article	IF	CITATIONS
37	New Drug: Caution Indicated. Archives of Internal Medicine, 2012, 172, 1681.	4.3	1
38	Time for Action on Drug Safety—Reply. JAMA - Journal of the American Medical Association, 1999, 281, 320.	3.8	1
39	Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease. Neurology, 2022, 98, 49-50.	1.5	O